Company news

TrivarX Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

TrivarX Appoints Emeritus Research for Phase 1 Study

November 10, 2026

September 2026 Quarterly Activities Report and Appendix 4C

October 29, 2026

September 2026 Quarterly Activities Report and Appendix 4C

October 29, 2026

Letter to Shareholders & Notice of AGM & Proxy Form

October 26, 2026

Syntro Health Appointed to Support Stabl-Im Clinical Program

October 21, 2026

Syntro Health Appointed to Support Stabl-Im Clinical Program

October 21, 2026

Change of Director's Interest Notice - David Trimboli

October 14, 2026

Change of Director's Interest Notice - Chris Ntoumenopoulos

October 14, 2026

Notification of cessation of securities - TRI

October 14, 2026

Appendix 4G

September 29, 2026

Corporate Governance Statement

September 29, 2026

2026 Annual Report

September 29, 2026

Stabl-Im Clinical Development Update

September 22, 2026

Notice of AGM and Closing Date for Director Nominations

September 21, 2026

Appendix 4E - Preliminary Final Report

August 26, 2026

June 2026 Quarterly Activities Report and Appendix 4C

July 28, 2026

Stabl-Im clinical trial supply milestone achieved

July 15, 2026

CRO Engaged to Advance Stabl-Im Phase 1 Trial

May 21, 2026

March 2026 Quarterly Activities Report and Appendix 4C

April 29, 2026

Dr Danielle Meyrick appointed as CEO

April 28, 2026

Appendix 4D & Half-Year Financial Report to 31 December 2025

February 24, 2026

December 2025 Quarterly Activities Report and Appendix 4C

January 29, 2026

Positive results from US-veteran mental health trial

December 17, 2025

TRI Exercises Option to Advance Acquisition of Stabl-Im

November 4, 2025

September 2025 Quarterly Activities Report and Appendix 4C

October 30, 2025

US-veteran mental health trial patient recruitment complete

October 21, 2025

Acquisition of Stabl-Im technology and Private Placement

October 15, 2025

Reinstatement to Official Quotation

October 15, 2025

Extension of Trading Suspension

October 12, 2025

Suspension from Quotation

October 8, 2025

Inadvertent Lift of Trading Halt

October 8, 2025

Pause in trade

October 7, 2025

Positive interim results from US-veteran focused trial

October 7, 2025

Trading Halt

October 6, 2025

Appendix 4E - Preliminary Final Report

August 28, 2025

June 2025 Quarterly Activities Report and Appendix 4C

July 30, 2025

First patient recruited in innovative mental health trial

June 18, 2025

March 2025 Quarterly Activities Report and Appendix 4C

April 30, 2025

IRB approval for trial with US Dept of Veterans Affairs

April 27, 2025

TrivarX Receives Firm Commitments to Raise $2.25 million

March 16, 2025

Trial with US Department of Veterans Affairs

March 12, 2025

Appendix 4D & Half-Year Financial Report to 31 December 2024

February 28, 2025

December 2024 Quarterly Activities Report and Appendix 4C

January 30, 2025

TrivarX Receives $1.03m R&D Tax Incentive

December 5, 2024

New AI Tool Expands Patient Reach and Market Opportunities

November 6, 2024

September 2024 Quarterly Activities Report and Appendix 4C

October 30, 2024

June 2024 Quarterly Activities Report and Appendix 4C

July 31, 2024

Positive Results from Phase 2 SAMDE Study

July 29, 2024

TrivarX Receives Firm Commitments to Raise $2.5 million

May 1, 2024

March 2024 Quarterly Activities Report and Appendix 4C

April 29, 2024

Older news releases →

Decks